A multicenter, randomised, double-blind, placebo-controlled phase IIIb study to evaluate the efficacy, safety and tolerability of Serelaxin when added to standard therapy in acute heart failure patients (CRLXA).
To demonstrate that serelaxin is superior to placebo in reducing cardiovascular death in acute heart failure patients during a follow-up period of 180 days.
A randomised, double blind, placebo-controlled trial.
Metra Marco and Teerlink John for the RLX030A2301
Dr Alasdair Gray
Dr Martin Denvir – Co PI
Dr James Dear – Co PI
Dr Kristin Haga – Investigator
Dr Alastair Moss – Investigator
Polly Black – Research Nurse
Kirsty Simpson – Research Nurse
Rachel O’Brien – Research Nurse
Julia Grahamslaw – Research Nurse
Patients who are admitted to hospital with acute heart failure, who have received IV diuretics and have a degree of impaired renal function.
Honorary Professor of Emergency Medicine & Clinical Director of the Emergency Department